deltatrials
Terminated PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT03879798

DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer

A Phase I/II Study of DS-3201b, an EZH1/2 Inhibitor, in Combination With Irinotecan in Patients With Recurrent Small Cell Lung Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Conditions Small Cell Lung Cancer
Interventions DS-3201b irinotecan
Updated 15 times since 2019 Last updated: Oct 8, 2024 Started: Mar 15, 2019 Primary completion: May 2, 2023 Completion: May 2, 2023
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Due to DLTs

Other terminated trials from Memorial Sloan Kettering Cancer Center

See all terminations from Memorial Sloan Kettering Cancer Center

Other Small Cell Lung Cancer trials with similar outcome

Browse all Small Cell Lung Cancer trials

This PHASE1/PHASE2 trial investigates Small Cell Lung Cancer and is currently terminated or withdrawn. Memorial Sloan Kettering Cancer Center leads this study, which shows 15 recorded versions since 2019 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Apr 2019 – ~Aug 2019 · 4 months · monthly snapshot~Aug 2019 – ~Sep 2019 · 31 days · monthly snapshot~Sep 2019 – ~Sep 2020 · 12 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~Apr 2022 · 12 months · monthly snapshot~Apr 2022 – ~Jul 2022 · 3 months · monthly snapshot~Jul 2022 – ~Sep 2022 · 2 months · monthly snapshot~Sep 2022 – ~May 2023 · 8 months · monthly snapshot~May 2023 – ~Jun 2023 · 31 days · monthly snapshot~Jun 2023 – ~May 2024 · 11 months · monthly snapshot~May 2024 – ~Jul 2024 · 2 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – present · 20 months · monthly snapshot

Change History

15 versions recorded

  1. Nov 2024 — Present [monthly]

    Terminated PHASE1/PHASE2

  2. Sep 2024 — Nov 2024 [monthly]

    Terminated PHASE1/PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE1/PHASE2

    Phase: PHASE1_PHASE2 → PHASE1/PHASE2

  4. May 2024 — Jul 2024 [monthly]

    Terminated PHASE1_PHASE2

    Status: Completed → Terminated

  5. Jun 2023 — May 2024 [monthly]

    Completed PHASE1_PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 10 earlier versions

  1. May 2023 — Jun 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

  2. Sep 2022 — May 2023 [monthly]

    Active Not Recruiting PHASE1_PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Jul 2022 — Sep 2022 [monthly]

    Recruiting PHASE1_PHASE2

  4. Apr 2022 — Jul 2022 [monthly]

    Recruiting PHASE1_PHASE2

  5. Apr 2021 — Apr 2022 [monthly]

    Recruiting PHASE1_PHASE2

  6. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE1_PHASE2

  7. Sep 2020 — Jan 2021 [monthly]

    Recruiting PHASE1_PHASE2

  8. Sep 2019 — Sep 2020 [monthly]

    Recruiting PHASE1_PHASE2

  9. Aug 2019 — Sep 2019 [monthly]

    Recruiting PHASE1_PHASE2

  10. Apr 2019 — Aug 2019 [monthly]

    Recruiting PHASE1_PHASE2

    First recorded

Mar 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Memorial Sloan Kettering Cancer Center
Data source: Memorial Sloan Kettering Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations